Joanne Billings is a Respiratory physician affiliated with University of Minnesota. OpenAlex indexes 70 publications with 4,410 citations (h-index 25); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
516 Delaware Street SE
University Of Minnesota Ph, Pwb Second Floor, Clinic 2a
Minneapolis, MN 55455
Telephone
612-626-6100Registry record last updated 13 Aug 2014.
Clinical trials
- Prospective Observational Study to Evaluate Biomarkers of Aminoglycoside Nephrotoxicity in Patients With Cystic Fibrosis
Sponsor: Foundation for the National Institutes of Health
- A Phase I Study of Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis.
Sponsor: University of Minnesota
- Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis.
Sponsor: Emphycorp
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Insmed, Inc.Program year20221 payment
- Insmed, Inc.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
35.1%Other respiratory system products24.7%Trikafta100%Part D≥16 patientsLeukotriene Receptor Antagonist5.3%Montelukast Sodium100%Part D<11 patients+ 2 more classes in this area
Metabolism & gastrointestinal
31.9%Antidiarrheal microorganisms10.8%Creon63%Zenpep37%Part D<11 patientsProton pump inhibitor9.1%Pantoprazole Sodium54%Omeprazole46%Part D<11 patients+ 2 more classes in this area
Anti-infectives
27.5%Macrolide Antimicrobial10.2%Azithromycin100%Part D≥12 patientsShort-acting sulfonamides5.1%Sulfamethoxazole-Trimethoprim100%Part D<11 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2001–2009 per NIH RePORTER. The latest:
- MULTIDOSE SAFETY AND TOLERABILITY STUDY OF LIPOSOMAL AMIKACIN FOR INHALATION (AR
University of Minnesota
FY2009$20,125M01RR000400 - KB001-03: A PHASE I/II RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-DOSE
University of Minnesota
FY2009$6,952M01RR000400 - EXPANDED ACCESS PROGRAM FOR AZTREONAMN LYSINE FOR INHALATION IN PATIENTS WITH CY
University of Minnesota
FY2009$5,854M01RR000400
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Chronic Obstructive Pulmonary Disease Exacerbations Increase the Risk of Subsequent Cardiovascular Events: A Longitudinal Analysis of the COPDGene Study
Journal of the American Heart Association
2024 - SARS-CoV-2 RNA and Nucleocapsid Antigen Are Blood Biomarkers Associated With Severe Disease Outcomes That Improve in Response to Remdesivir
The Journal of Infectious Diseases
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Blazar, MD
University of Minnesota
Jay Cohn, MD
University of Minnesota
Julia Steinberger, MD
University of Minnesota
Charles Herzog, MD
University of Minnesota
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”